News
UNCY
5.77
+3.22%
0.18
Guggenheim Keeps Their Buy Rating on Unicycive Therapeutics (UNCY)
TipRanks · 12/31/2025 08:25
De-Risked NDA Resubmission and TDAPA Tailwinds Support Buy Rating on Unicycive and OLC Commercial Upside
TipRanks · 12/30/2025 17:05
Unicycive resubmits NDA for hyperphosphatemia asset
Seeking Alpha · 12/29/2025 21:25
Unicycive Therapeutics resubmits NDA for oxylanthanum carbonate
TipRanks · 12/29/2025 12:10
Unicycive Therapeutics Has Resubmitted Its 505(b)(2) New Drug Application To FDA For Oxylanthanum Carbonate For Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis
Benzinga · 12/29/2025 12:08
Unicycive Resubmits NDA for Oxylanthanum Carbonate to FDA
Reuters · 12/29/2025 12:05
UNICYCIVE THERAPEUTICS ANNOUNCES RESUBMISSION OF NEW DRUG APPLICATION (NDA) FOR OXYLANTHANUM CARBONATE (OLC)
Reuters · 12/29/2025 12:05
UNICYCIVE THERAPEUTICS INC - NDA SUBMISSION REVIEW EXPECTED WITHIN 6 MONTHS PER PRESCRIPTION DRUG USER FEE ACT
Reuters · 12/29/2025 12:05
Weekly Report: what happened at UNCY last week (1222-1226)?
Weekly Report · 12/29/2025 09:37
Weekly Report: what happened at UNCY last week (1215-1219)?
Weekly Report · 12/22/2025 09:37
Weekly Report: what happened at UNCY last week (1208-1212)?
Weekly Report · 12/15/2025 09:41
Weekly Report: what happened at UNCY last week (1201-1205)?
Weekly Report · 12/08/2025 09:40
Unicycive Therapeutics unveils new kidney disease treatment pipeline in latest corporate presentation
Reuters · 12/02/2025 20:22
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close
NASDAQ · 12/02/2025 04:02
Weekly Report: what happened at UNCY last week (1124-1128)?
Weekly Report · 12/01/2025 09:38
Unicycive Therapeutics to Participate in Piper Sandler Healthcare Conference
Reuters · 11/25/2025 12:05
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
Barchart · 11/25/2025 06:05
Weekly Report: what happened at UNCY last week (1117-1121)?
Weekly Report · 11/24/2025 09:41
Weekly Report: what happened at UNCY last week (1110-1114)?
Weekly Report · 11/17/2025 09:41
More
Webull provides a variety of real-time UNCY stock news. You can receive the latest news about Unicycive Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.